Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
Mabwell Bioscience’s anti-ST2 monoclonal antibody (mAb) has led to a 40% reduction in annualised severe exacerbations in patients with chronic…
Respiratory
-
-
ArkBio commences Phase II study of AK0610 for RSV prevention
Shanghai Ark Biopharmaceutical (ArkBio) has commenced a randomised Phase II study to evaluate the fully human monoclonal antibody, AK0610, for…
-
Tvardi Therapeutics’ stock crashes on Phase II IPF flop
Tvardi Therapeutics’ stock has crashed more than 80% after the company revealed that its idiopathic pulmonary fibrosis (IPF) candidate flunked…
-
Celea Therapeutics engages regulators ahead of Phase III deupirfenidone IPF trial
Celea Therapeutics is speaking with regulators about launching a Phase III trial of its idiopathic pulmonary fibrosis (IPF) drug deupirfenidone…
-
Sensory Cloud’s SC0023 reveals cough reduction in Phase II trial
Sensory Cloud has announced positive results from the Phase II REACH trial of SC0023 conducted at King Saud University Medical…
-
Osivax initiates vaccination in OVX836 trial for influenza A
Biopharmaceutical company Osivax has vaccinated the first subject in its randomised Phase IIb trial of OVX836 for influenza A. The…
-
Abdera reports initial data from Phase Ia trial of radiopharmaceutical therapy
Abdera Therapeutics has reported initial data from its Phase Ia study of the radiopharmaceutical biologic therapy, ABD-147, in treating individuals…
-
AstraZeneca’s Tagrisso combination shows survival benefit in lung cancer trial
AstraZeneca's Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy, has shown a significant improvement in overall survival (OS) in…
-
Hutchmed finalises subject enrolment for Orpathys and Tagrisso combo trial
Hutchmed has completed subject enrolment in the randomised Phase III SANOVO trial in China, which is evaluating the combination of…
-
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan
Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC clinical trial of a disulfide small molecule, LP-300,…
